AFM
EDSA icon

Anson Funds Management’s Edesa Biotech EDSA Stock Holding History

Anson Funds Management’s Portfolio EDSA Stock Details EDSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-627
Closed -$300K – 51
2017
Q1 		$300K Buy
+627
New +$333K 0.12% 36
2016
Q4 		– Sell
-2,426
Closed -$1.71M – 96
2016
Q3 		$1.71M Sell
2,426
-444
-15% -$372K 0.37% 33
2016
Q2 		$3.22M Buy
+2,870
New +$2.96M 0.61% 28

Other funds holding EDSA

AG
Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
WAS
WESPAC Advisors SoCal Pasadena, California $560M AUM 37.11% 1-Year Est. Return
ASN
Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
CFD
Creative Financial Designs Kokomo, Indiana $1.65B AUM 15.6% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Anson Funds Management's EDSA Position: Q2 2017 in Review

Anson Funds Management sold out of Edesa Biotech (EDSA) in Q2 2017, closing a stake of 627 shares — an estimated $300K sold.

Anson Funds Management first reported a position in EDSA in Q2 2016 and held it in 3 quarters. The position peaked at $3.22M in Q2 2016. 9 funds tracked by Wall St. Rank hold EDSA as of Q2 2017.

  • Anson Funds Management reported no remaining Edesa Biotech position as of Q2 2017 after selling out during the quarter.
  • Anson Funds Management sold 627 Edesa Biotech shares in Q2 2017, an estimated $300K.
  • Anson Funds Management first reported a position in Edesa Biotech in Q2 2016 and held it in 3 quarters.
  • Anson Funds Management's Edesa Biotech position peaked at $3.22M in Q2 2016.
  • 9 funds tracked by Wall St. Rank held Edesa Biotech as of Q2 2017.

Based on Anson Funds Management's 13F filing for Q2 2017, filed 14 Aug 2017.